Rigontec GmbH (Munich, Germany) develops synthetic ligands of a novel receptor of the innate immune system, Retinoic acid Inducible Gene I (RIG-I), which recognizes viral RNA. RNA motifs that activate RIG-I promote the destruction of diseased cells and the induction of a lasting immune memory thereby treating and preventing recurrence of disease.

Rigontec’s lead compound RGT100, a proprietary first-in-class product targeting RIG-I, has demonstrated substantial tumor regression and systemic anti-tumor activity including long-term protection against tumor rechallenge. RGT100 is currently in clinical development.

Sten Verland, PhD, MSc

Senior Partner

Mobile: +45 24 22 19 69
Email Click here to contact